This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, R.-Y. Articles by Swaab, D. F. Search for Related Content PubMed PubMed Citation Articles by Liu, R.-Y. Articles by Swaab, D. F. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Medline Plus Health Information Alzheimer's Disease Seniors' Health

Decreased Melatonin Levels in Postmortem Cerebrospinal Fluid in Relation to Aging, Alzheimer’s Disease, and Apolipoprotein E-4/4 Genotype¹

Netherlands Institute for Brain Research (R.-Y.L., J.-N.Z., J.v.H., M.A.H., D.F.S.), 1105 AZ Amsterdam ZO, The Netherlands; and Anhui Geriatrics Institute, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230032, People’s Republic of China

Address all correspondence and requests for reprints to: D. F, Swaab, M.D., Ph.D., Netherlands Institute for Brain Research, Meibergdreef 33, 1105 AZ Amsterdam ZO, The Netherlands. E-mail: t.eikelboom{at}nih.knaw.nl

Sleep disruption, nightly restlessness, sundowning, and other circadian disturbances are frequently seen in Alzheimer’s disease (AD) patients. Changes in the suprachiasmatic nucleus and pineal gland are thought to be the biological basis for these behavioral disturbances. Melatonin is the main endocrine message for circadian rhythmicity from the pineal. To determine whether melatonin production was affected in AD, melatonin levels were determined in the cerebrospinal fluid (CSF) of 85 patients with AD (mean age, 75 ± 1.1 yr) and in 82 age-matched controls (mean age, 76 ± 1.4 yr). Ventricular postmortem CSF was collected from clinically and neuropathologically well defined AD patients and from control subjects without primary neurological or psychiatric disease. In old control subjects (>80 yr of age), CSF melatonin levels were half of those in control subjects of 41–80 yr of age [176 ± 58 (n = 29) and 330 ± 66 (n = 53) pg/mL, respectively; P = 0.016]. We did not find a diurnal rhythm in CSF melatonin levels in control subjects. In AD patients the CSF melatonin levels were only one fifth (55 ± 7 pg/mL) of those in control subjects (273 ± 47 pg/mL; P = 0.0001). There was no difference in the CSF melatonin levels between the presenile (42 ± 11 pg/mL; n = 21) and the senile (59 ± 8 pg/mL; n = 64; P = 0.35) AD patients. The melatonin level in AD patients expressing apolipoprotein E-3/4 (71 ± 11 pg/mL) was significantly higher than that in patients expressing apolipoprotein E-4/4 (32 ± 8 pg/ml; P = 0.02). In the AD patients no significant correlation was observed between age of onset or duration of AD and CSF melatonin levels. In the present study, a dramatic decrease in the CSF melatonin levels was found in old control subjects and even more so in AD patients. Whether supplementation of melatonin may indeed improve behavioral disturbances in AD patients should be investigated.

This article has been cited by other articles:

				A. T. Blaszczyk and M. Mathys Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia Journal of Pharmacy Practice, February 1, 2007; 20(1): 13 - 28. [Abstract] [PDF]

				Y.-H. Wu, D. F. Fischer, A. Kalsbeek, M.-L. Garidou-Boof, J. van der Vliet, C. van Heijningen, R.-Y. Liu, J.-N. Zhou, and D. F. Swaab Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock" FASEB J, September 1, 2006; 20(11): 1874 - 1876. [Abstract] [Full Text] [PDF]

				J. A. Yesavage, L. Friedman, H. Kraemer, J. R. Tinklenberg, A. Salehi, A. Noda, J. L. Taylor, R. O'Hara, and G. Murphy Sleep/Wake Disruption in Alzheimer's Disease: APOE Status and Longitudinal Course J Geriatr Psychiatry Neurol, March 1, 2004; 17(1): 20 - 24. [Abstract] [PDF]

				Y.-H. Wu, M. G. P. Feenstra, J.-N. Zhou, R.-Y. Liu, J. S. Torano, H. J. M. Van Kan, D. F. Fischer, R. Ravid, and D. F. Swaab Molecular Changes Underlying Reduced Pineal Melatonin Levels in Alzheimer Disease: Alterations in Preclinical and Clinical Stages J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5898 - 5906. [Abstract] [Full Text] [PDF]

				D. L. Bliwise, D. B. Rye, B. Dihenia, and P. Gurecki Greater Daytime Sleepiness in Subcortical Stroke Relative to Parkinson's Disease and Alzheimer's Disease J Geriatr Psychiatry Neurol, June 1, 2002; 15(2): 61 - 67. [Abstract] [PDF]

				Vijayalaxmi, C. R. Thomas Jr, R. J. Reiter, and T. S. Herman Melatonin: From Basic Research to Cancer Treatment Clinics J. Clin. Oncol., May 15, 2002; 20(10): 2575 - 2601. [Abstract] [Full Text] [PDF]

				L. Volicer, D. G. Harper, B. C. Manning, R. Goldstein, and A. Satlin Sundowning and Circadian Rhythms in Alzheimer's Disease Am J Psychiatry, May 1, 2001; 158(5): 704 - 711. [Abstract] [Full Text]

				D. G. Harper, E. G. Stopa, A. C. McKee, A. Satlin, P. C. Harlan, R. Goldstein, and L. Volicer Differential Circadian Rhythm Disturbances in Men with Alzheimer Disease and Frontotemporal Degeneration Arch Gen Psychiatry, April 1, 2001; 58(4): 353 - 360. [Abstract] [Full Text] [PDF]

				H. J. Bursztajn Melatonin Therapy: From Benzodiazepine-Dependent Insomnia to Authenticity and Autonomy Arch Intern Med, November 8, 1999; 159(20): 2393 - 2395. [Full Text] [PDF]

				D. C. Skinner and B. Malpaux High Melatonin Concentrations in Third Ventricular Cerebrospinal Fluid Are Not due to Galen Vein Blood Recirculating through the Choroid Plexus Endocrinology, October 1, 1999; 140(10): 4399 - 4405. [Abstract] [Full Text]